XERS Stock Analysis: Buy, Sell, or Hold?

XERS - Xeris Biopharma Holdings, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$5.43
0.02 (0.46%) β–²
5d: -3.3%
30d: -11.36%
90d: -26.39%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation

XERS is down 5.7% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 23 OI. Call ratio: 100% View Scanner →

Strength: 7.9/10

Get Alerted When XERS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

πŸ’‘
Bottom Line:
βœ… BUY SIGNAL: XERS trading at deep discount. Market pricing in -10.7% annual earnings decline, creating value opportunity for patient investors.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$14.79
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.18
40.9% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: XERS is currently trading at $5.42, which is considered oversold relative to its 30-day fair value range of $5.42 to $6.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.6) compared to its historical average (20.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.7% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, XERS is in a downtrend. Immediate support is located at $5.25, while resistance sits at $5.68.

Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+106.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position OVERSOLD
Fair Price Range $5.42 - $6.49
Company Quality Score 53/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 79.5%

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (45/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 106.3% below Wall St target ($11.14)

Fair Price Analysis

30-Day Fair Range $5.42 - $6.49
Current vs Fair Value OVERSOLD

Support & Resistance Levels

Support Level $5.25
Resistance Level $5.69
Current Trend Downtrend
Technical data as of Mar 27, 2026

Fundamental Context

Forward P/E (Next Year Est.) 14.57
Wall Street Target $11.14 (+106.3%)
Revenue Growth (YoY) 42.8%
Profit Margin 0.2%
Valuation Discount vs History -10.7% cheaper
PE vs Historical 14.6 vs 20.5 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -10.7% (market-implied from PE analysis)
1-Year Target $4.86 (-10%)
2-Year Target $4.37 (-19%)
3-Year Target $3.94 (-27%)
3-Yr Target (if PE normalizes) (PE: 15β†’21) $5.54 (+3%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 22.4, Growth: 160.4%) $28.01 (+419%)
Base: (SPY PE: 14.6, Growth: 160.4%) $18.23 (+238%)
Bear: (PE: 12.4, Growth: 160.4%) $15.49 (+187%)
πŸ’‘ Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.6 to 20.5
Stabilization Target: $7.60 (+40.7%)
PE Expansion Potential: +40.7%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: March 30, 2026 10:27 AM ET
Data refreshes hourly during market hours. Next update: 11:27 AM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht SELL 16667 shares 2026-03-02
Beth Hecht SELL 16667 shares 2026-02-02
Kevin Mcculloch SELL 15000 shares 2026-01-08

Unlock Insider Activity

See real-time buying/selling by company executives for XERS.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
AXSM
Axsome Therapeutics Inc
STRONG BUY
19 analysts
$222 62 BUY
CYTK
Cytokinetics Inc
STRONG BUY
21 analysts
$92 62 BUY
RARE
Ultragenyx
STRONG BUY
20 analysts
$54 54 HOLD
INCY
Incyte Corporation
HOLD
27 analysts
$108 63 BUY
MDGL
Madrigal Pharmaceuticals…
STRONG BUY
15 analysts
$669 65 BUY

More Analysis for XERS

XERS Technical Chart XERS Price Prediction XERS Earnings Date XERS Investment Advisor XERS Fair Price Analyzer XERS Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals